Evaluation of 48-week daily teriparatide treatment with DXA-based hip structure analysis in elderly female patients with rheumatoid arthritis

Article Sidebar

PDF
Published Apr 30, 2015

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

Sho Mokuda
Department of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama

Abstract

   Objectives: The purposes of the present study were to clarify the effects on the structural strength of the femoral neck bones in elderly RA patients being treated with teriparatide.

Methods: Fifty female RA patients were enrolled. We investigated the bone mineral density (BMD) of the lumbar vertebrae and femoral neck, and performed a hip structure analysis (HSA) using dual-energy X-ray absorptiometry (DXA) during a 48-week treatment with teriparatide (20 µg/day).

Results: The mean age was 74.5 years, and the mean duration of RA was 23.0 years. The percent change in the lumbar BMD was +5.8% (mean, 24 weeks, p<0.01) and +8.0% (mean, 48 weeks, p<0.01). On the other hand, there were no statistically significant differences in the femoral neck BMD changes at either 24 or 48 weeks (p=0.72 and p=0.56, respectively). The percentage change from baseline in the buckling ratio of the femoral neck was -16.8% (improve) at 48 weeks (p=0.004), because of cortical thickening. There were no significant differences in the section modulus (SM) or cross-sectional area (CSA).

Conclusions: The femoral neck bone strength increased with teriparatide treatment in elderly female RA patients.

Article Details

How to Cite
MOKUDA, Sho. Evaluation of 48-week daily teriparatide treatment with DXA-based hip structure analysis in elderly female patients with rheumatoid arthritis. Medical Research Archives, [S.l.], n. 3, apr. 2015. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/129>. Date accessed: 15 nov. 2024.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Keywords
DXA-based hip structure analysis; glucocorticoid; osteoporosis; rheumatoid arthritis; teriparatide.
Issue
No 3 (2015)
Section
Research Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

Amin S, Gabriel SE, Achenbach SJ, Atkinson EJ, Melton LJ 3rd: Are young women and men with rheumatoid arthritis at risk for fragility fractures? A population-based study. J Rheumatol. 2013; 40: 1669-76.

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31: 315-24.

Beck TJ, Ruff CB, Warden KE, Scott WW Jr, Rao GU: Predicting femoral neck strength from bone mineral data. A structural approach. Invest Radiol. 1990; 25: 6-18.

Bonnick SL, Beck TJ, Cosman F, Hochberg MC, Wang H, de Papp AE: DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass. Osteoporos Int. 2009; 20: 911-21.

Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, et al.: Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2008; 93: 852-60.

Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, et al.: Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002; 112: 281-9.

Ebina K, Hashimoto J, Shi K, Kashii M, Hirao M, Yoshikawa H. Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients. Osteoporos Int. 2014; 25: 2755-65.

Genant HK, Wu CY, van Kuijk C, Nevitt MC: Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993; 8: 1137-48.

Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK: Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000; 43: 522-30.

Ito M, Sone T, Fukunaga M: Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis. J Bone Miner Metab. 2010; 28: 334-41.

Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N: The diagnosis of osteoporosis. J Bone Miner Res. 1994; 9: 1137-41.

Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, et al.: Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005; 16: 510-6.

Li Z, Meredith MP, Hoseyni MS: A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med. 2001; 20: 3175-88.

Martin R, Burr D. Non-invasive measurement of long bone cross-sectional moment of inertia by photon absorptiometry. J Biomech 1984; 17: 195-201.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344: 1434-41.

Ørstavik RE, Haugeberg G, Mowinckel P, Høiseth A, Uhlig T, Falch JA, et al.: Vertebral deformities in rheumatoid arthritis: a comparison with population-based controls. Arch Intern Med. 2004; 164: 420-5.

Roux C. Osteoporosis in inflammatory joint diseases. Osteoporos Int. 2011; 22: 421-33.

Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al.: Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357: 2028-39.

Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al.: Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009; 60: 3346-55.

Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD: Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002; 17: 1-10.

Takada J, Miki T, Imanishi Y, Nakatsuka K, Wada H, Naka H, et al.: Effects of raloxifene treatment on the structural geometry of the proximal femur in Japanese women with osteoporosis. J Bone Miner Metab. 2010; 28: 561-7.

Takada J, Katahira G, Iba K, Yoshizaki T, Yamashita T: Hip structure analysis of bisphosphonate-treated Japanese postmenopausal women with osteoporosis. J Bone Miner Metab. 2011; 29: 458-65.

Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, et al.: Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone. 2005; 36: 948-58.

van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C: Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006, 54: 3104-12.　

Vis M, Güler-Yüksel M, Lems WF. Can bone loss in rheumatoid arthritis be prevented? Osteoporos Int. 2013; 24: 2541-53.